[惊吓]_老虎社区_美港股上老虎

KSHoSG
2021-04-23

[惊吓]

Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>

The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate. What happe

Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":372817774,"tweetId":"372817774","gmtCreate":1619190666398,"gmtModify":1634287860882,"author":{"id":3575616552570301,"idStr":"3575616552570301","authorId":3575616552570301,"authorIdStr":"3575616552570301","name":"KSHoSG","avatar":"https://static.tigerbbs.com/f9e9c60ddd65dd7dca218423e8951ee3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>[惊吓]&nbsp;</body></html>","htmlText":"<html><head></head><body>[惊吓]&nbsp;</body></html>","text":"[惊吓]","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/372817774","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://www.laohu8.com/m/news/1122047796?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国之后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today<blockquote>为什么Inovio股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\n Motley Fool 2021-04-23 23:05\n\n</h4>\n</header>\n<article>\nThe biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.<blockquote>该生物技术公司刚刚失去了其COVID-19候选疫苗后期研究的资金。</blockquote> What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Inovio Pharmaceuticals&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.<blockquote>本公司之股份Inovio制药公司截至美国东部时间周五上午11点05分，（纳斯达克：INO）股价暴跌26.8%。在该公司宣布美国之后，股价大幅下跌。国防部将停止资助评估其COVID-19候选疫苗INO-4800的3期研究。</blockquote> So what<blockquote>那又怎样</blockquote> The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.<blockquote>INO-4800 3期研究资金的损失对Inovio来说是一个巨大的挫折，因此今天这一消息传出后该生物技术股票的大幅抛售并不令人意外。</blockquote> <img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"<blockquote>为什么国防部停止资助后期研究？Inovio表示，该部门化学、生物、辐射和核防御联合项目执行办公室（JPEO-CBRND）告诉该公司：“该决定源于随着疫苗的快速部署而不断变化的COVID-19环境。这一决定不是对获奖者或产品的反映，而是与前“曲速行动”相关的快速变化的环境对未来产品相关决策的影响。”</blockquote> That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.<blockquote>这听起来有点像情侣分手时的老台词：“不是你，是我。”然而，在这种情况下，这是有道理的。</blockquote> The U.S. already has supply deals in place with&nbsp;Pfizer,Moderna, and&nbsp;Johnson &amp; Johnson&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;AstraZeneca&nbsp;and&nbsp;Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.<blockquote>美国已经与辉瑞,现代，和强生公司足够给每个美国人接种疫苗了。COVID-19疫苗来自阿斯利康和Novavax也可能很快赢得紧急使用授权。在这一点上，投资测试另一种疫苗根本不是政府资金的明智使用。</blockquote> Now what<blockquote>现在怎么办</blockquote> The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.<blockquote>国防部仍将资助正在进行的INO-4800的2期研究。Inovio现在计划主要在美国境外进行该疫苗的后期研究。它还在评估另一种针对冠状病毒变种的候选药物INO-4802。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\"> Motley Fool </a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1,"symbols_score_info":{"INO":0.9}},"isVote":1,"tweetType":1,"viewCount":2484,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}